Sitryx snags a potential $880 million deal on new immune-metabolic medicines

31 March 2020
sitryx_large

UK-based biopharmaceutical company Sitryx, focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, has signed an exclusive global licensing and research collaboration with US pharma major Eli Lilly (NYSE: LLY).

The collaboration will study up to four novel pre-clinical targets identified by Sitryx, which was formed in 2018 with intellectual property licenced from GlaxoSmithKline LSE: GSK), that could lead to potential new medicines for autoimmune diseases.

$50 million upfront

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology